Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in Early Stage NSCLC
NCT02938624Phase 1Completed
- Start
- Jan 2017
- Primary completion
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (4 cohorts). Primary endpoints: Dose Limiting Toxicities at 24 months, Percentage of Residual Viable Tumor Cells at 24 months and 1 more. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02938624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938624.